check_circleStudy Completed

Anemia

Single dose group stratified study in renal impaired and healthy aged and gender matched subjects

Trial purpose

Safety, tolerability, pharmacokinetics and pharmacodynamics will be investigated in a single dose group stratified study in renal impaired and healthy subjects.

Key Participants Requirements

Sex

Both

Age

18 - 79 Years

Trial summary

Enrollment Goal
56
Trial Dates
March 2011 - August 2014
Phase
Phase 1
Could I Receive a placebo
No
Products
Molidustat (BAY85-3934)
Accepts Healthy Volunteer
Yes

Where to participate

StatusInstitutionLocation
Completed
Kiel, 24105, Germany

Primary Outcome

  • Number of participants with adverse events
    date_rangeTime Frame:
    Up to 4 weeks
    enhanced_encryption
    Safety Issue:
    Yes

Secondary Outcome

  • Area under the plasma concentration versus time curve (AUC) of BAY85-3934
    date_rangeTime Frame:
    Day 0 to day 4
    enhanced_encryption
    Safety Issue:
    No
  • Peak Plasma Concentration (Cmax) of BAY85-3934
    date_rangeTime Frame:
    Day 0 to day 4
    enhanced_encryption
    Safety Issue:
    No
  • Dose-normalized area under the plasma concentration-time curve (AUCnorm) of BAY85-3934
    date_rangeTime Frame:
    Day 0 to day 4
    enhanced_encryption
    Safety Issue:
    No
  • Dose- and body weight-normalised Cmax (Cmax-norm) of BAY85-3934
    date_rangeTime Frame:
    Day 0 to day 4
    enhanced_encryption
    Safety Issue:
    No

Trial design

Investigation of pharmacokinetics, safety, tolerability, and pharmacodynamic effects of BAY85-3934 in male and female subjects with renal impairment and in age- and weight-matched healthy subjects following a single oral dose of 20 mg and 40 mg (optional) BAY 85-3934 administered as tablets in a single-center, non-randomized, non-controlled, non-blinded, observational study with group stratification
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Other
Allocation
Non-randomized
Blinding
Open Label
Assignment
Single Group Assignment
Trial Arms
3